Advertisement

MYGN

Myriad Genetics, Inc.

Healthcare · USD

Set alert

Price alert · MYGN

All alert types
6.35 USD -0.32 -4.80%
As of Oct 30, 2026 Extended hours 6.35 0.00%
Bid
6.33 × 2
Ask
6.34 × 2
6.29 Day range 6.66
2.86 52-week range 8.18
YTD
+3.25%
1 year
-20.13%
Open
6.51
Prev close
6.67
Mkt cap
607.38M
Vol
1.50M
Avg vol
2.64M
EPS
-1.18
P/E
0.00
Div yield
0.00%
More statistics
Low
6.29
High
6.66
Forward P/E
71.53
Beta
1.89
Short ratio
4.83
Inst. own
103.89%
Dividend
0.00
Ex-div date
50-d avg
13.32
200-d avg
21.11
1y target
19.41

2Y chart

Chart tools
Interval
MYGN two-year price chart2.747.7612.817.822.8Oct 24Mar 25Aug 25Jan 26Jun 26Oct 26

Key statistics

Market cap
979.65M
Enterprise value
1.05B
Trailing P/E
0.00
Forward P/E
71.53
PEG ratio
0.00
Price / sales
1.17
Price / book
1.40
EPS (TTM)
-1.41
Beta
1.89
Dividend yield
0.00%
Payout ratio
0.00%
Profit margin
-15.20%
Revenue (TTM)
837.60M
Revenue growth
7.10%
Free cash flow
11.76M
Total cash
102.40M
Total debt
140.30M
Return on equity
-17.15%
Shares outstanding
91.30M
Short % of float
8.31%
50-day average
13.32
200-day average
21.11

Analyst view

Consensus: buy

Buy
Price target (mean) 19.41 +205.7% upside
Target (low)
11.00
Target (mean)
19.41
Target (high)
29.00
Ratings (0m) 16 8 buy · 5 hold · 3 sell
  • Strong buy4
  • Buy4
  • Hold5
  • Sell1
  • Strong sell2

Next earnings

Consensus EPS estimate -0.06447.

Earnings history

Financials — quick view

All financials
MYGN Revenue — quarterly 190.70M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MYGN Net income — quarterly -43.20M
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026
MYGN EPS — quarterly -0.46
2022-Q3 20222022-Q4 20222023-Q1 20232023-Q2 20232023-Q3 20232023-Q4 20232024-Q1 20242024-Q2 20242024-Q3 20242024-Q4 20242025-Q1 20252025-Q2 20252025-Q3 20252025-Q4 20252026-Q1 20262026-Q2 2026

Earnings

MYGN recent earnings
Report dateQuarter endingEPS estimateEPS reportedSurpriseSurprise %
Feb 24, 2025Dec 1, 20240.030.030.000.00%
Nov 7, 2024Sep 1, 20240.020.06+0.04+200.00%
Aug 6, 2024Jun 1, 2024—0.05+0.06+600.00%
Feb 27, 2024Dec 1, 20230.020.04+0.02+100.00%

Upgrades / downgrades

MYGN analyst upgrades and downgrades
DateFirmActionFromTo
Feb 25, 2025Raymond JamesreitOutperformOutperform
Feb 25, 2025UBSmainNeutralNeutral
Feb 12, 2025Craig-Halluminit—Buy
Jan 30, 2025Piper SandlermainNeutralNeutral
Jan 28, 2025Goldman SachsmainBuyBuy
Jan 16, 2025Stephens & Co.reitEqual-WeightEqual-Weight

About Myriad Genetics, Inc.

Myriad Genetics, Inc., a genetic testing and precision medicine company, develops genetic tests in the United States and internationally. It offers molecular diagnostic tests for oncology, and women's and pharmacogenomics. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status with ovarian cancer. It offers Prolaris Prostate Cancer Prognostic Test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. It provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit, hyperactivity disorder, and other mental health conditions. It has a strategic collaboration with Illumina, Inc., Memorial Sloan Kettering Cancer Center, the University of Texas MD Anderson Cancer Center, SimonMed, Onsite Women's Health, and Flatiron Health, Inc.; and collaboration to study the use of MRD testing in breast cancer. The company was incorporated in 1992 and is headquartered in Salt Lake City, Utah.

Sector
Healthcare
Industry
Diagnostics & Research
Country
United States
Website
myriad.com

News

Your note

Sign in to keep a note on MYGN — it syncs with the Stock Master app.

Insider holders

MYGN insider holders
InsiderRelationLatest transactionDateShares held
ANCONA MARGARETOfficerSaleAug 20, 202479,366
DAVIS MARK STEVENDirectorStock Award(Grant)Dec 9, 202422,816
DIAZ PAUL JChief Executive OfficerSaleOct 10, 2024962,378
DREISMANN HEINRICHDirectorSaleSep 8, 2024121,648
FOX JENNIFER LYNNEOfficerStock Award(Grant)Sep 2, 202461,771
KUMAR RASHMIDirectorSaleAug 18, 202477,392

Institution ownership

MYGN institution ownership
Holder% heldSharesValueReported
Blackrock Inc.17.47%15,907,593170.69MDec 30, 2024
Vanguard Group Inc11.63%10,591,043113.64MDec 30, 2024
Wellington Management Group, LLP6.60%6,004,59864.43MDec 30, 2024
State Street Corporation6.07%5,525,70559.29MDec 30, 2024
Millennium Management Llc4.77%4,345,19646.62MDec 30, 2024
Glenview Capital Management, Llc4.57%4,157,32444.61MDec 30, 2024

Fund ownership

MYGN fund ownership
Holder% heldSharesValueReported
iShares Core S&P Smallcap ETF6.47%5,889,36563.19MDec 30, 2024
Vanguard Explorer Fund, Inc.3.51%3,193,90234.27MOct 30, 2024
Vanguard Total Stock Market Index Fund2.97%2,701,05428.98MSep 29, 2024
iShares Russell 2000 ETF2.66%2,417,66125.94MDec 30, 2024
Vanguard Small-Cap Index Fund2.37%2,157,13823.15MSep 29, 2024
SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF2.08%1,892,40920.31MDec 30, 2024
Advertisement